In the present sutdy, we have examined the relationship between the CaMKII (Ca 2 + /calmodulindependent protein kinase II) pathway and endothelial dysfunction in aortas from GK (GotoKakizaki) Type 2 diabetic rats. The ACh (acetylcholine)-induced relaxation and NO production were each attenuated in diabetic aortas (compared with those from age-matched control rats). ACh-stimulated Ser 1177 -eNOS (endothelial NO synthase) phosphorylation was significantly decreased in diabetic aortas (compared with their controls). ACh markedly increased the CaMKII phosphorylation level within endothelial cells only in control aortas (as assessed by immunohistochemistry and Western blotting). ACh-stimulated Thr 286 -CaMKII phosphorylation within endothelial cells was significantly decreased in diabetic aortas (compared with their controls). The ACh-induced relaxations, NO production, eNOS phosphorylation, and CaMKII phosphorylation were inhibited by KN93 and/or by lavendustin C (inhibitors of CaMKII) in control aortas, but not in diabetic ones. Pre-incubation of aortic strips with a PP (protein phosphatase)-1 inhibitor, PPI2 (protein phosphatase inhibitor 2), or with a PP2A inhibitor, CA (cantharidic acid), corrected the above abnormalities in diabetic aortas. The expression of PP2A type A subunit was increased in diabetic aortas. The ACh-stimulated Thr 320 -phosphorylation level of PP1α was lower in diabetic aortas than in their controls, but the total PP1α protein level was not different. These results suggest that the aortic relaxation responses, NO production, and eNOS activity mediated by CaMKII phosphorylation are decreased in this Type 2 diabetic model, and that these impairments of CaMKII signalling may be, at least in part, due to enhancements of PP1α activity and PP2A expression.
INTRODUCTION
Type 2 diabetes mellitus is an important risk factor for the development of macrovascular diseases and for increased BP (blood pressure) [1, 2] . However, the exact relationship between Type 2 diabetes and CVD (cardiovascular disease) is still not completely understood, and indeed is the subject of some dispute. This is at least partly because Type 2 diabetes is often part of a complex array of abnormalities referred to as the 'metabolic syndrome,' which is frequently accompanied by hypertension and obesity [1] [2] [3] . Several lines of evidence suggest that endothelial dysfunction could play a key role in the development of macroangiopathy in diabetes patients and in animal models of diabetes [4] [5] [6] [7] . Although we and others have demonstrated that both endothelial function and NO production are impaired in aortic strips from diabetic models [4] [5] [6] [7] [8] , these results seem to conflict with findings indicating that the expressions of the mRNA and protein for eNOS [endothelial NOS (NO synthase)] are increased or not changed in such aortas [9] [10] [11] . A plausible explanation may be that in intact cells, NO synthesis can be regulated independently of changes in eNOS enzyme activity. Recent studies have suggested that decreased phosphorylation of eNOS and uncoupling of eNOS, with consequently less NO, is one of the major underlying causes of the endothelial dysfunction found in diabetes [12] .
In endothelial cells, the main signal-transduction pathway for agonist-stimulated eNOS activation depends on the Ca 2 + /calmodulin complex. At the cellular level, evidence is accumulating that a rise in intracellular Ca 2 + is necessary for the induction of NO production by agonists such as ACh (acetylcholine), histamine and bradykinin [13, 14] , but not by stimuli such as fluid shear stress, VEGF (vascular endothelial growth factor) and insulin [11, [15] [16] [17] . CaMKII (Ca 2 + /calmodulindependent protein kinase II) is a multifunctional serine/threonine protein kinase that is believed to transduce the downstream effects of Ca 2 + /calmodulin [18] . It has been shown that CaMKII is expressed in cultured endothelial cells from several vessels, and that it may be involved in NO synthesis as a result of Ca 2 + -dependent activation of eNOS [19, 20] . Furthermore, some studies have suggested a role for CaMKII in the induction of NO in the endothelium by bradykinin or ACh, since inhibition of such agonistinduced activations of CaMKII leads to impaired NO availability [21, 22] . It seems likely that Ca 2 + -dependent, physiological NO production and vasorelaxation are at least in part mediated by a CaMKII-dependent enzymatic activation of eNOS. Although the endothelium-specific regulation of CaMKII is now beginning to be properly understood [23] , there are few in vivo data to indicate a potentially significant role of CaMKII in endothelial cell pathophysiology.
Abnormal regulation of CaMKII/eNOS/NO may be one of the several factors contributing to the endothelial dysfunction seen in diabetic mellitus. We decided to examine the rat aorta, a vessel that is mainly NOS (nitric oxide synthase) dependent in its endotheliummediated relaxations [10] . The aim of the present study was to investigate the relationship between the CaMKII signalling system and endothelium-dependent relaxation in aortas from Type 2 diabetic rats. We also asked whether aortas from control and Type 2 diabetic rats might differ in their expression profiles of CaMKII and its phosphatase enzymes.
MATERIALS AND METHODS

Reagents
( − )-Arterenol, A23187 (calcimycin A23187), indomethacin, SNP (sodium nitroprusside) dehydrate, l-NNA (N G -nitro-l-arginine) and PE (phenylephrine) were purchased from Sigma. ACh chloride was from Daiichi Pharmaceuticals. KN92, KN93, lavendustin C, human recombinant PPI2 (protein phosphatase inhibitor 2) from Escherichia coli, CA (cantharidic acid), and fenvalerate were from Merck. KN92, KN93, lavendustin C and CA were dissolved in DMSO. The final concentration of DMSO in the bath was 0.5 %, which had no effects on the tissues under test. Drug solutions were made up using saline, with indomethacin being dissolved first in a small amount of 0.1 mol/l Na 2 CO 3 solution. All concentrations are expressed as the final molar concentration of the base in the organ bath.
Animals and experimental design
Male GK (Goto-Kakizaki) rats and Wistar control rats were obtained at the age of 4 weeks (Clea). All animals were allowed a standard laboratory diet (MF; Oriental Yeast Industry) and water ad libitum. This study was approved by the Hoshi University Animal Care and Use Committee, and all studies were conducted in accordance with 'Guide for the Care and Use of Laboratory Animals' published by the US National Institutes of Health, and 'Guide for the Care and Use of Laboratory Animals' adopted by the Committee on the Care and Use of Laboratory Animals of Hoshi University (which is accredited by the Ministry of Education, Culture, Sports, Science, and Technology, Japan). The experiments described were performed when the rats were 32-38 weeks old. using the commercially available enzyme kit (Wako Chemical), while plasma insulin (excluding proinsulin) was measured by enzyme immunoassay using Rat Insulin ELISA KIT (S-type) (Shibayagi). For BP measurements, a given rat was kept in a constant-temperature hot box at 37
• C for 15 min. Then, its BP was measured by the tail-cuff method using a BP analyser (BP-98A; Softron) at least 5 min after the rat had been put in a restrainer for the purpose of measuring.
Measurement of isometric force
A section of the thoracic aorta (from the region between the aortic arch and the diaphragm) and/or the superior mesenteric artery were removed and placed in oxygenated, modified KHS (Krebs-Henseleit solution).
The aorta (cut into helical strips) was placed in a bath containing 10 ml of KHS, with one end of each strip connected to a tissue holder and the other to a force-displacement transducer, as previously described [8] . For the relaxation studies, strips were precontracted with an equieffective concentration of NA (noradrenaline, 5×10 − 8 -3×10 − 7 mol/l) (so that the tension developed in response to NA was similar among all groups). All tissues were equilibrated for 40 min in the presence of 10 − 5 mol/l indomethacin (to block cyclooxygenase) before administration of NA. When the NA-induced contraction had reached a plateau level, ACh (10 − 9 -10 − 5 mol/l), SNP (10 − 10 -10 − 5 mol/l) or A23187 (10 − 9 -10 − 6 mol/l) was added in a cumulative manner. When the effects of l-NNA (10 − 4 mol/l), KN92 (5×10 − 6 mol/l), KN93 (10 − 6 mol/l or 5×10 − 6 mol/l), lavendustin C (10 − 6 mol/l), PPI2 (10 − 9 mol/l), CA (5×10 − 8 mol/l) or fanvalerate (4×10 − 9 mol/l) on the responses to these relaxant agents were to be examined, the appropriate inhibitor was added to the bath 20 min before the application of NA.
The mesenteric artery was carefully cleaned of all fat and connective tissue, and ring segments 2 mm in length were suspended by a pair of stainless steel pins in a well-oxygenated bath containing 10 ml of KHS at 37
• C. The rings were stretched until an optimal resting tension of 1.0 g was loaded, and then allowed to equilibrate for at least 60 min. Force generation was monitored by means of an isometric transducer. For the relaxation studies, mesenteric rings were precontracted with PE (10 − 6 mol/l). 
Measurement of NO x (combined nitrate + nitrite)
The concentration of NO x in the effluent from each tissue was sampled and assayed by the method described previously (ENO20; Eicom) [10] . Each aorta was cut into transverse rings 10 mm in length. These were placed in 0.5 ml of KHS or Ca 2 + -free medium at 37
• C. Samples of effluent were collected on two occasions as follows: sample 1, for a 20-min period after application of 10 − 7 mol/l ACh or 10 − 7 mol/l A23187 (with or without 10 − 6 mol/l KN93, 10 − 9 mol/l PPI2, 5×10 . 'Ca 2 + -free' experiments were conducted in nominally Ca 2 + -free KHS containing 0.5 mM EGTA, as previously described [13] . The concentration of NO x in the KHS and the reliability of the reduction column were examined in each experiment.
Measurement of the protein expressions of eNOS, CaMKII, PP1α, PP2A-A and PP2A-B (by Western blotting) Aortas (two pooled vessels) were homogenized in icecold lysis buffer containing 5×10 − 2 mol/l Tris/HCl buffer (pH 7.5), 150 mM NaCl, 1 % Triton X-100 and protease-inhibitor cocktail, as previously described [10] . Homogenates were centrifuged at 13 000 g for 5 min. The supernatant was sonicated at 4
• C and the proteins were solubilized in Laemmli's buffer containing mercaptoethanol. The protein concentration was determined by means of a BCA (bicinchoninic acid) protein assay reagent kit (Pierce). Samples (24 μg/lane) were resolved by electrophoresis on SDS/10 % PAGE gels and transferred on to PDVF membranes. Briefly, after blocking the residual protein sites on the membrane, the membrane was incubated with anti-eNOS antibody (1:1000 dilution; BD Bioscience), anti-CaMKII antibody (1:1000 dilution; Cell Signaling Technology), anti-PP (protein phosphatase)1α antibody (1:1000 dilution; Cell Signaling Technology), anti-PP2A-A antibody (1:1000 dilution; Cell Signaling Technology), anti-SG2NA antibody (PP2A-B type subunit, 1:1000 dilution; Cell Signaling Technology), or β-actin antibody (1:5000 dilution; Sigma) in blocking solution. To normalize the data, we used β-actin as a housekeeping protein. (1:1000 dilution; Cell Signaling Technology) in blocking solution. To normalize the data, we used β-actin as a housekeeping protein. For the analysis, detection of phosphoprotein was followed by membrane stripping and by detection of total protein expression and then of β-actin. The absorbances of the bands on the film were quantified using densitometry, with correction for the absorbance of the corresponding β-actin band. Ratios were calculated for the absorbance of phosphorylated eNOS, CaMKII or PP1α over that of the corresponding total-protein band. Note that the Western blotting data were obtained from runs on separate gels, but under the same conditions.
Measurements of
Immunohistochemistry for Thr 286 CaMKII phosphorylation
Immunohistochemistry was carried out using a method described previously [25] . After incubation, those same aortic strips were embedded in OCT Compound (Sakura). Non-specific binding was blocked by treatment with a drop of normal horse serum in ImmunoBlock (DS Pharma Biomedical) for 20 min before incubation with anti-phospho CaMKII Thr 286 (1:50 dilution; Cell Signaling Technology) or anti-vWF (von Willebrand factor; 1:200; Sigma) in ImmnoBlock overnight at 4
• C. Tissue sections were then incubated for 30 min at room temperature (20 • C) with an anti-IgG CY3 conjugate (1:100 dilution; Sigma) secondary antibody. Sections of rat aorta embedded in VECTASHIELD (Vector Laboratories) were examined using a fluorescence (6) microscope. Photographs of the specimens were digitized for data analysis. The areas of the positive regions were quantified using LSM 5 EXCITER software with custom-written macros.
Statistical analysis
Each relaxation response is expressed as a percentage of the contraction induced by NA. Values are means + − S.E.M. When appropriate, statistical differences were assessed by Dunnett's test for multiple comparisons after a one-or two-way ANOVA, P < 0.05 being regarded as significant. Statistical comparisons between concentration-response curves were made using a oneway ANOVA, with post hoc correction for multiple comparisons by Bonferroni's test, P < 0.05 again being considered significant.
RESULTS
General parameters
As indicated in Table 1 , at the time of the experiment (when the rats were 32-38 weeks old), the body weight of the GK rats was lower than that of the age-matched nondiabetic control Wistar rats. At the time of the experiment, all GK rats (non-fasted) exhibited hyperglycaemia, their blood glucose levels being significantly higher than those of the Wistar rats (also non-fasted). The plasma insulin level was significantly higher in GK rats than in Wistar rats. Plasma total cholesterol and HDL levels were not different between control and diabetic rats. Systolic BP was not different between control and diabetic rats.
Relaxation responses to ACh, SNP and A23187
When the NA (5×10 − 8 -3×10 − 7 mol/l)-induced aortic contraction had reached a plateau, ACh, A23187 or SNP was added cumulatively (with indomethacin being present to eliminate the effects of prostaglandins). The ACh-induced relaxation was significantly weaker in the 32-38 weeks diabetic group (R max 65.1 + − 4.1 %, − logEC 50 7.25 + − 0.06) than in the controls (R max To investigate the contribution made by the CaMKII pathway to ACh-induced and A23187-induced relaxations in the rat aorta, we added ACh or A23187 cumulatively to aortas precontracted by NA in the presence of the CaMKII inhibitor KN93, the CaMKII inhibitor lavendustin C [21] [22] [23] , the PP1 inhibitor PPI2 or the PP2A inhibitor CA [26, 27] . Studies by other groups have shown that endothelial CaMKII is KN93-sensitive [21] [22] [23] . In the control groups, the AChinduced relaxation was markedly weaker than control in aortas treated with a CaMKII inhibitor (KN93, R max 77.9 + − 3.3 %, − logEC 50 6.92 + − 0.08) or lavendustin C, R max 56.5 + − 5.6 %, − logEC 50 6.96 + − 0.09) (Figure 2A ). In the diabetic group, however, this relaxation showed no change following pre-incubation with KN93 (R max 71.7 + − 6.2 %, − logEC 50 6.92 + − 0.09) or lavendustin C (R max 57.1 + − 3.9 %, − logEC 50 7.09 + − 0.10) ( Figure 2B ). In control aortic strips that had been pretreated with one of these CaMKII inhibitors (Figure 2A) , the AChinduced relaxation was decreased to a level comparable to that seen in the inhibitor-untreated diabetic group ( Figure 2B ). is shown only when it is larger than the symbol. * P < 0.05 compared with the non-treated control group, †P < 0.05 compared with the non-treated diabetic group.
Since several PP inhibitors have been shown to enhance CaMKII activities [28] [29] [30] [31] , we examined the effect of a PP1 inhibitor, PPI2, and that of a PP2A inhibitor, CA, on the ACh-induced relaxation in diabetic and control aortas found in the present study. In the control group, the ACh-induced relaxation showed no change following pre-incubation with either 10 − 9 mol/l PPI2 (R max 99.8 + − 0.01 %, − logEC 50 7.60 + − 0.07) or 5×10 − 8 mol/l CA (R max 100 %, − logEC 50 7.55 + − 0.08) ( Figure 2C ). In the diabetic aortas, the ACh-induced relaxation was enhanced by pre-incubation with either PPI2 (R max 94.6 + − 1.9 %, − logEC 50 7.41 + − 0.16) or CA (R max 95.7 + − 2.2 %, − logEC 50 7.34 + − 0.15) ( Figure 2D) . A PP 2B inhibitor, fenvalerate (4×10 − 9 mol/l), did not affect the ACh-induced relaxation in either control or diabetic aortas (results not shown).
To investigate to what extent, if any, CaMKIIdependent relaxation might be affected in mesenteric arteries from diabetic rats, we examined ACh-induced relaxation in the combined presence of 10 − 5 mol/l indomethacin, 10 − 7 mol/l apamin and 10 − 5 mol/l TRAM-34. Under these conditions, the NO-mediated relaxation tended to be slightly (not significantly) weaker in rings from diabetic rats than in those from control rats. In each (control or diabetic) group, the AChinduced mesenteric artery relaxation was not significantly changed by treatment with KN93, but it was completely abolished by co-treatment with l-NNA, indomethacin, apamin and TRAM-34 (results not shown). These observations suggest that in the superior mesenteric artery, the ACh-induced NO-dependent relaxation is not regulated by the CaMKII-signalling pathway.
With indomethacin present to eliminate the effects of prostaglandins, the A23187-induced relaxation was not changed by treatment with KN93 in either the control or diabetic group of aortas ( Figures 3A and 3B ). Without indomethacin, the A23187-induced relaxation (10 − 9 -10 − 6 mol/l) in the control group was markedly weaker in aortas treated with 5×10 − 6 mol/l KN93 (results not shown). An inactive KN93 analogue, 5×10 − 6 mol/l KN92, did not affect the ACh-induced relaxation in either the control or the diabetic group ( Figure 3C ). The SNP-induced relaxation was not changed by treatment with either KN93 (Figure 3D ) or lavendustin C (10 − 6 mol/l; results not shown) in control or diabetic aortas.
Analysis of NOS activity by measurement of phosphorylated eNOS expression and NO production, and effects of ACh and A23187
In view of the published evidence that the eNOS/NO signalling pathway plays a major role in endotheliumdependent relaxation in the aorta, we performed an analysis of this pathway using ACh-and A23187- stimulated aortas from the control and diabetic groups of rats (Figures 4 and 5) . Use of anti-eNOS antibody and anti-phospho eNOS Ser 1177 allowed detection of an immunoreactive protein with a molecular weight of 140 kDa, as previously described [25, 32] . We found that in endothelium-denuded aortas, phosphorylated eNOS levels were below the lower limit of detection (results not shown). ACh significantly increased both the NO x level and the eNOS phosphorylation level in aortas from control rats, but did not alter these levels in diabetic aortas (compared with basal levels). The ACh-stimulated NO x level and eNOS phosphorylation level were each significantly decreased in the diabetics (compared with their controls). When control aortic rings were pretreated with KN93, the ACh-stimulated NO x level and eNOS phosphorylation level were each was not different between the diabetic and control groups. The A23187-stimulated aortic level of NO x was increased in the controls and tended to be increased in the diabetic group. In each group of aortas, the A23187-stimulated level of NO x showed no change following pre-incubation with KN93. (C) In Ca 2 + -free medium, the ACh-stimulated level of NO x was decreased in aortas from the diabetic group. In control aortas, the ACh-stimulated level of NO x in Ca 2 + -free medium was lower in the presence of KN93. In Ca 2 + -free medium with BAPTA/AM (5×10 − 6 mol/l), the ACh-induced increase in the NO x levels was abolished in aortas from both groups. Values are means + − S.E.M. from six to ten determinations. * P < 0.05 compared with ACh-or A23187-unstimulated (Basal). †P < 0.05 compared with ACh-stimulated controls. ‡P < 0.05 compared with ACh-stimulated diabetics.
significantly decreased to a level comparable to that seen in the ACh-stimulated diabetic group. In diabetic aortas, the ACh-stimulated NO x and eNOS phosphorylation levels were not significantly affected by pretreatment with KN93. In the control group, the ACh-induced NO x and eNOS phosphorylation levels showed no change following pre-incubation with 10 − 9 mol/l PPI2 or 5×10 − 8 mol/l CA. In the diabetic group, however, the ACh-induced NO x and eNOS phosphorylation levels were enhanced by such treatment with either PPI2 or CA ( Figures 4A and 5) . A23187 increased the NO x level in aortic strips from both the control and diabetic groups (compared with basal NO x levels). The A23187-stimulated NO x level tended (non-significantly) to be decreased in the diabetics (compared with their controls). The A23187-stimulated NO x ( Figure 4B ) and eNOS phosphorylation levels (results not shown) were not changed by KN93 treatment in either control or diabetic aortas. In Ca 2 + -free medium, ACh significantly increased the NO x level in aortas from control rats, but this level was significantly lower in the diabetics (compared with their controls). When control aortas were pretreated with KN93 in Ca 2 + -free medium, the ACh-stimulated NO x level was significantly decreased to a level comparable with that seen in the ACh-stimulated diabetic group. When each of these groups was pretreated with a chelator of the intracellular Ca 2 + store, BAPTA/AM, in Ca 2 + -free medium, the ACh-induced stimulation of the NO x level was abolished ( Figure 4C ).
Measurements of phosphorylated CaMKII expression, and its localization within endothelial cells, and the effects of ACh
In response to Ca 2 + -mobilizing agents, CaMKII is autophosphorylated at Thr 286 , which renders the kinase constitutively active. Here, we used Western blot analysis and immunohistochemistry to examine whether in aortic endothelial cells, the phosphorylated CaMKII level might be altered in diabetic rats. Use of antiCaMKII and anti-phospho-CaMKII (Thr 286 ) antibodies allowed detection of an immunoreactive protein with a molecular weight of 50 kDa. The aortic expression of total CaMKII tended to be decreased (non-significantly) in the diabetic group ( Figure 6A) . ACh significantly increased the CaMKII phosphorylation level in aortas from the controls, but not in those from diabetic rats (compared with basal levels). The ACh-stimulated CaMKII phosphorylation level was significantly lower in the diabetics than in their controls. In diabetic aortas, the ACh-stimulated CaMKII phosphorylation level was not significantly affected by pretreatment with KN93 ( Figure 6B ). When control aortic strips were pretreated with KN93, the ACh-stimulated CaMKII phosphorylation level was significantly decreased to a level comparable to that seen in the diabetic group under the same conditions. In the control group, the ACh-induced CaMKII phosphorylation level showed no change following pre-incubation with either 10 − 9 mol/l PPI2 or 5×10 − 8 mol/l CA. In the diabetic aortas, however, the ACh-stimulated CaMKII phosphorylation level was enhanced by pre-incubation with either of those inhibitors ( Figure 6B) . Thus, the results obtained for the phosphorylation levels of CaMKII were similar to those described above for eNOS activity/ NO production.
We performed immunohistochemistry for CaMKII phosphorylation and for vWF, an endothelial marker. Positive staining for vWF was detected only in endothelial cells, not in smooth muscle cells (Figures 7A and 7E) . Following ACh-stimulation, CaMKII phosphorylation staining was found in the aorta co-localized with vWF ( Figures 7A, 7C, 7E and 7G ). In the endothelial layer, the ACh-stimulated strips ( Figures 7C and 7G ) displayed increased CaMKII phosphorylation staining (compared with basal levels; Figures 7B and 7F) . The ACh-stimulated CaMKII phosphorylation staining was decreased in the diabetics (compared with their controls) ( Figures 7G compared with 7C ). This observed staining in endothelial cells was considerably attenuated by pretreatment with KN93 in each group of aortas ( Figures 7D and 7H ). These data provide strong evidence that phosphorylation of CaMKII within the endothelial cell plays a crucial role in the response to ACh, and that such phosphorylation is reduced in the diabetic aorta. Expression of total PP1α, phosphorylated Thr 320 PP1α, PP2A-A and PP2A-B proteins PP1 and PP2A appear to play important physiological roles in the dephosphorylation of CaMKII [28, 30, 31, 33] . Use of anti-PP1α and anti-phosphorylated Thr 320 PP1α antibodies allowed detection of an immunoreactive protein with a molecular weight of 38 kDa. The aortic expression of total PP1α was not different between the diabetic and control groups ( Figure 8A ). Previously, it was reported that Thr 320 phosphorylation of PP1α inhibits its activities [33] . In the unstimulated (basal) condition, the phosphorylated Thr 320 PP1α level was not different between the diabetic and control groups. In aortas stimulated with ACh ( Figure 8B ), the expression of phosphorylated Thr 320 PP1α was significantly elevated in the controls (compared with the basal level), and it was significantly decreased in the diabetic group (compared with the ACh-stimulated controls). Use of anti-PP2A-A and anti-PP2A-B antibodies allowed detection of immunoreactive proteins with molecular weights of 62 and 95 kDa, respectively. The aortic expression of total PP2A-A protein was greater in the diabetic group than in the controls (Figure 8C ), but the expression of total PP2A-B was not different between these groups ( Figure 8D ).
DISCUSSION
The most important observations made in the present study, which compared aortas from Type 2 diabetic rats with those from age-matched controls, were that certain ACh-induced effects (relaxation, NO production and Ser 1177 eNOS phosphorylation) were much weaker in the diabetic aortas. Our data suggest that this may be due, at least in part, to a reduction in Thr 286 CaMKII phosphorylation in the present type of diabetes, perhaps reflecting enhancements of the dephosphorylation of Thr 286 CaMKII by PP1α and PP2A ( Figure 9 ). The present ACh-induced relaxation was markedly diminished in both control and diabetic aortas by treatment with l-NNA, an inhibitor of NOS, suggesting that the ACh-induced response is regulated by NO released from the endothelium. Furthermore, our findings may indicate a mechanism by which in the aortic endothelial-cell layer, CaMKII phosphorylation can affect endothelial function; that is, by regulating eNOS phosphorylation. Our results indicate that in endothelial cells from control aortas (in which we confirmed the presence of ACh-stimulated Thr 286 phospho-CaMKII by immunohistochemistry), the ACh-induced endotheliumderived relaxation and NO production may be mediated via eNOS phosphorylation. Moreover, these effects of ACh were decreased by treatment with a CaMKII inhibitor, suggesting that CaMKII phosphorylation is involved in the ACh-induced enhancement of the effect of eNOS on NO production.
Interestingly, in our study addition of a CaMKII inhibitor made no significant difference to A23187-induced responses (aortic relaxation, eNOS phosphorylation or NO production) in either control or diabetic aortas, whereas the ACh-induced responses were decreased by a CaMKII inhibitor in control aortas. These observations suggest that the A23187-induced relaxation and NO production are not regulated by the CaMKII signal pathway. In endothelial cells, the main mechanism for agonist-stimulated eNOS activation depends on the binding of a Ca 2 + /CaM complex to eNOS via an increase in intracellular Ca 2 + (release of Ca 2 + from its intracellular stores and an influx of extracellular Ca 2 + ) [13, 14] . Several laboratories have shown that even with a low intracellular concentration of Ca 2 + , shear stress, insulin and ACh can activate eNOS, and that these activations occur via several serine/threonine protein kinases, such as Akt (also known as protein kinase B) [11, 15, 16] . Likewise, CaMKII reportedly enhances Ser 1177 eNOS phosphorylation via activation of serine/threonine protein kinases, such as Akt and ERK (extracellular-signal-regulated kinase) [21, 32, 34] . In the diabetic state, enhancements of PP2A and PP1α lead to an impairment of CaMKII phosphorylation, and thereby to a decrease in eNOS phosphorylation within aortic endothelial cells, with the result being that associated endothelial function is impaired. Ca, calcium; CaM, calmodulin; NO synthase, endothelial NOS.
Possibly, CaMKII-dependent eNOS activation by the release of a high concentration of Ca 2 + is only weakly related to the induction of NO production, while the release of a low concentration of Ca 2 + and/or a receptormediated signal is closely related to NO production via at least a few intermediate serine/threonine protein kinases. In aortic strips in Ca 2 + -free medium, the intracellular Ca 2 + concentration can increase only via release of Ca 2 + from its intracellular stores. When strips from control rats were pretreated with a CaMKII inhibitor in Ca 2 + -free medium, the ACh-stimulated NO production was decreased to a level comparable with that seen in the AChstimulated diabetic group ( Figure 4C) . Interestingly, previous studies using brain tissue have suggested that at a basal Ca 2 + concentration, calmodulin may be 'trapped' on CaMKII [35] . In our present study, the AChinduced Ser 1177 eNOS phosphorylation was inhibited in control aortas by treatment with KN93, an inhibitor of CaMKII, suggesting that ACh-induced relaxation and NO production are regulated directly and/or indirectly by eNOS phosphorylation via CaMKII.
The major finding made in the present study is that the mechanism underlying endothelial dysfunction in the aorta in Type 2 diabetic rats may involve impairment of the CaMKII pathway. In our diabetic model, both the aortic NO production and eNOS phosphorylation induced by ACh were attenuated compared with those in the controls. When a CaMKII inhibitor was applied to control rat aortas in the present study, the ACh-induced relaxation and the ACh-stimulated NOS activity were each decreased to a level comparable with that seen in the corresponding diabetic group. These results suggest that the impairment of the ACh-induced relaxation response observed in the present diabetic aortas may be due to decreases in the NO release and NOS activity mediated through the CaMKII pathway. We therefore hypothesized that both the protein expression and activities of CaMKII might be altered in the present type of diabetes. In fact, the expression level of total CaMKII protein tended to be decreased in our diabetic group, and the Thr 286 CaMKII phosphorylation level induced by ACh was significantly lower in aortic endothelial cells from diabetic rats than in those from their controls. These findings are consistent with those relating to the magnitude of the ACh-induced relaxations in diabetic rats, and directly suggest that relaxation responses and NO production mediated via the CaMKII pathway are attenuated in the present Type 2 diabetic rat model, and that these attenuations are due, at least in part, to the observed decrease in the phosphorylation of CaMKII (Figure 9 ).
The central role played by protein phosphorylation/dephosphorylation in cellular regulation suggests that diabetic states will involve perturbations in the balance between protein kinase and PP activities [36, 37] . Dephosphorylations of Thr 286 by the serine/threonine PPs PP1, PP2A and PP2C have been shown to occur in vitro, and the phosphatases responsible for counterregulating the endogenous CaMKII activity have been identified in a variety of cell-types [28] [29] [30] [31] . Previously, in a gene-profiling study, we reported that the mRNA expressions of SG2NA B isoform (PP2A-B type subunit) and protein tyrosine phosphatase type IV A are increased in aortic endothelial cells derived from streptozotocininduced diabetic rats, a finding that supports the emerging roles of newly identified molecules in the process underlying endothelial dysfunction in diabetic states [23] . In the present study, we found: (i) that the aortic expression of PP2A-A protein, but not of PP2A-B, was increased in the diabetic group, (ii) that the AChstimulated expression of phosphorylated Thr 320 PP1α (note that Thr 320 phosphorylation of PP1α inhibits its activities) was lower in the diabetic group than in their controls, and (iii) that the ACh-stimulated CaMKII phosphorylation level, and the ACh-induced relaxation and eNOS activities were all enhanced by pre-incubation with either PP1 inhibitor or PP2A inhibitor in the diabetic aortas. Thus the results obtained for the activity levels of both PP2A-A and PP1α are consistent with those described above showing impaired CaMKII activities in the diabetic aorta. Indeed, our results suggest that the enhancements of PP2A and PP1α seen in the present diabetic state may have led to an impairment of the CaMKII pathway, and thereby to a decrease in eNOS phosphorylation within aortic endothelial cells, with the result being that associated endothelial function was impaired.
We found in the present study that in superior mesenteric arteries, the ACh-induced relaxation was not changed by treatment with KN93 in either the control or diabetic group. These observations suggest that in that artery, other pathways, not involving CaMKII signalling, regulate the ACh-induced NO-dependent relaxation.
At the cellular level and in large arteries, evidence is accumulating that serine/threonine protein kinases, such as CaMKII, PKA (protein kinase A) and Akt, enhance Ser 1177 eNOS phosphorylation [21, 32, 34, 38] . However, little is known about the pathways affecting endothelial NOS activities in vivo in small arteries, including mesenteric arteries. Furthermore, we have reported previously that, in mesenteric arteries, the main factor/pathway for endothelium-dependent relaxation is dependent on EDHF [37] . It seems likely that the contribution made by the CaMKII signal pathway to NOS activities differs between aorta and mesenteric artery. In the present study, we did not examine changes in the responses to PKA, Akt and other kinases. Since there might be cross-talk between CaMKII and these kinases, and this might be altered in diabetic states, we need to conduct further studies to examine the effects of CaMKII and several other kinases in such rats, focusing on the endothelial dysfunction seen in diabetic rats.
Recent progress in defining the key insulin-signal suggests that CaMKII phosphorylation may be causally involved in important events in insulin-stimulated glucose uptake, such as GLUT4 glucose translocation and Akt phosphorylation [39, 40] . The impairments of CaMKII activity and CaMKII expression observed in our Type 2 diabetic rats may be secondary to the insulinresistance present in such rats. It is unclear at present, however, which missing action of insulin in endothelial cells might be responsible for decreasing the CaMKII expression/activation level in the diabetic aorta, and indeed it is conceivable that this effect might be initiated by changes in the plasma glucose level or in the level of any of several hormones, including insulin. Several studies have strongly suggested that abnormal regulation of protein phosphorylation, including phosphorylations of PP1, and PP2A, is associated with the insulin-resistance seen in Type 2 diabetes in humans and in animal models [41] . Actually, high glucose levels increase PP2A activity in human cultured VSMCs (vascular smooth muscle cells) [42] . We suspect that in Type 2 diabetic rats, the relative lack of action of insulin and the hyperglycaemia together cause an impairment of CaMKII activity and enhancements of PP1 and PP2, resulting in impairments of CaMKII-mediated endothelial function and NO production. However, this hypothesis remains to be tested in future studies.
In conclusion, in the present study we found: (i) that CaMKII plays important roles in endothelium-derived relaxation and NO production in the rat aorta, (ii) that the impaired NO production in aortic endothelial cells that we detected in Type 2 diabetic rats may be attributable to a reduced CaMKII activity level, which in turn may result from increased PP1α and PP2A activities. We believe that our findings should stimulate further interest in CaMKII as a potential therapeutic target in the continuing efforts to reduce diabetes-associated vascular diseases, especially those involving impairments of the functions of endothelial cells.
